The company said net sales for Q3 ended December 31, 2024 were $1.827 billion, up 17.1% from $1.560 billion in the same period last year, and increased 16.6% on a constant currency basis.

1. 01

   The company said net sales for Q3 ended December 31, 2024 were $1.827 billion, up 17.1% from $1.560 billion in the same period last year, and increased 16.6% on a constant currency basis.

2. 02

   The company said gross margin for Q3 was 60.3% compared to 58.7% in the same period last year, and operating income was $567.3 million compared to $487.9 million. Diluted earnings per share were $3.00 compared to $2.52 in the prior-year period.

3. 03

   The company said UGG brand net sales for Q3 increased 16.1% to $1.244 billion, and HOKA brand net sales increased 23.7% to $530.9 million. Teva brand net sales decreased 6.0% to $24.1 million.

4. 04

   The company said net sales for fiscal 2025 ending March 31, 2025 are expected to increase approximately 15% to $4.9 billion. It provided diluted earnings per share guidance in the range of $5.75 to $5.80, which does not take into account the impact from any potential future share repurchases.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.